Menu
  • Join
  • Login
  • Contact
 

Search abstracts


In-situ gelling controlled release injection of rivastigmine to treat Alzheimers disease

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: SAIF, Alasoul (King abdulaziz university, Saudi Arabia)
  • Co-author(s): Rawan othman Almadfaa: pharmacy, king abdulaziz university, jeddah, Saudi Arabia
    Alasoul Saif: pharmacy, king abdulaziz university, jeddah,Saudi Arabia
    Hatoun labban:pharmacy, king abdulaziz university, jeddah,Saudi Arabia
  • Abstract:

    Background

    Alzheimer is a neurodegenerative disease that is characterized by deterioration of cognitive & memory functions. Rivastigmine (RIV) is one of the most common drugs available for the treatment. The main challenge for its use is the frequent dosing and compliance to medications. As a result, Alzheimer's patients stop taking rivastigmine

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses